Whooping cough - Clinical trials 

  • Clinical trials

Clinical trials for Whooping cough

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Whooping cough. For all clinical trials, go to clinical trials search

This list shows clinical trials for Whooping cough

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Whooping cough
Title Recruitment status Location
Montelukast for Persistent Cough in Young People and Adults Recruiting United Kingdom
A phase II, open-label, randomized, multicentre study to evaluate the feasibility of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine co-administered with Prevenar compared with Pediacel co-administered with Menjugate and Prevenar, when given in healthy infants as a three-dose primary vaccination course at 2, 3 and 4 months of age and to evaluate Menitorix given to these children as a booster dose at 12 months of age - DTPA-IPV=HIB-MENC-TT-001 PRI Not Recruiting United Kingdom
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants Not recruiting United Kingdom
Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children Not recruiting United Kingdom
A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses to booster doses in the second year of life. (code: Sched2) - Sched2 Not Recruiting United Kingdom
Prems Under New Schedule (PUNS) Authorised United Kingdom
An open label randomised controlled study to evaluate the induction of immune memory following infant vaccination with a glyco-conjugate Neisseria meningitidis serogroup C vaccine and to assess the immunological impact of administering routine infant immunisations in consistent versus alternating limbs - Can we reduce the number of vaccine injections for children? Authorised United Kingdom
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi Pasteur MSD’s dTpa-IPV vaccine (Repevax), when co-administered with GSK Biologicals’ MMR vaccine (Priorix) in 3 and 4-year-old healthy children. - DTPA-IPV (BOOSTRIX-IPV)-009 Authorised United Kingdom
Estudio de fase 2b, abierto, aleatorizado, de grupos paralelos y multicéntrico para evaluar la seguridad, tolerabilidad e inmunogenicidad de la vacuna recombinante contra el meningococo del grupo B de Novartis, administrada con o sin vacunaciones infantiles sistemáticas a niños sanos de acuerdo con diferentes esquemas de inmunización. A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules Authorised United Kingdom
A phase III open (partially double-blind), controlled, multicenter, multicountry primary & booster vaccination study to demonstrate the non-inferiority of the meningococcal serogroup C response of GlaxoSmithKline Biologicals’ Hib-MenC vaccine co-administered with Infanrix™-IPV versus a licensed meningococcal serogroup C vaccine co-administered with Pediacel™ when given according to a 2, 3, 4 month schedule and immunogenicity of Hib-MenC when given as a booster dose at 12-15 months of age. - HIB-MENC-TT-012 HIB-MENC-TT-013 BST 012 Authorised United Kingdom
  • Link to Directgov – public services all in one place
  • The Information Standard - Certified member